Related references
Note: Only part of the references are listed.The Cell Biology of LRRK2 in Parkinson's Disease
Ahsan Usmani et al.
MOLECULAR AND CELLULAR BIOLOGY (2021)
Bicyclic β-Sheet Mimetics that Target the Transcriptional Coactivator β-Catenin and Inhibit Wnt Signaling
Mathias Wendt et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Allosteric Inhibition of Parkinson's-Linked LRRK2 by Constrained Peptides
Leah G. Helton et al.
ACS CHEMICAL BIOLOGY (2021)
Impact of Type II LRRK2 inhibitors on signaling and mitophagy
Anna Tasegian et al.
BIOCHEMICAL JOURNAL (2021)
Structural analysis of the full-length human LRRK2
Alexander Myasnikov et al.
CELL (2021)
Protein-Protein Interface Topology as a Predictor of Secondary Structure and Molecular Function Using Convolutional Deep Learning
Benjamin Bouvier
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2021)
Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2
Sven H. Schmidt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease
Dominika Natalia Wojewska et al.
BIOMOLECULES (2021)
Is Parkinson's disease a chronic low-grade inflammatory bowel disease?
Malvyne Rolli-Derkinderen et al.
JOURNAL OF NEUROLOGY (2020)
N-locking stabilization of covalent helical peptides: Application to Bfl-1 antagonists
Carlo Baggio et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2020)
Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present)
Xiao Ding et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
Targeting Plasmodium with constrained peptides and peptidomimetics
Leah G. Helton et al.
IUBMB LIFE (2020)
LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease
Emily M. Rocha et al.
NEUROBIOLOGY OF DISEASE (2020)
The LRRK2 N-terminal domain influences vesicle trafficking: impact of the E193K variant
Algerta Marku et al.
SCIENTIFIC REPORTS (2020)
Application and Structural Analysis of Triazole-Bridged Disulfide Mimetics in Cyclic Peptides
Andrew M. White et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease
Matthew Taylor et al.
CURRENT OPINION IN CELL BIOLOGY (2020)
Is there an antagonistic pleiotropic effect of a LRRK2 mutation on leprosy and Parkinson's disease?
Deng-Feng Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits
Marco A. S. Baptista et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Binding of the Human 14-3-3 Isoforms to Distinct Sites in the Leucine-Rich Repeat Kinase 2
Jascha T. Manschwetus et al.
FRONTIERS IN NEUROSCIENCE (2020)
The In Situ Structure of Parkinson's Disease-Linked LRRK2
Reika Watanabe et al.
CELL (2020)
Allosteric inhibition of LRRK2, where are we now
Ahmed Soliman et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2020)
Identification of peptides interfering with the LRRK2/PP1 interaction
Chang Zhi Dong et al.
PLOS ONE (2020)
Structure of LRRK2 in Parkinson's disease and model for microtubule interaction
C. K. Deniston et al.
NATURE (2020)
A rationally designed bicyclic peptide remodels Aβ42 aggregation in vitro and reduces its toxicity in a worm model of Alzheimer's disease
Tatsuya Ikenoue et al.
SCIENTIFIC REPORTS (2020)
Kinase Domain Is a Dynamic Hub for Driving LRRK2 Allostery
Susan S. Taylor et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2020)
The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson's Disease
Hardy J. Rideout et al.
FRONTIERS IN NEUROSCIENCE (2020)
Selective Inhibitors of G2019S-LRRK2 Kinase Activity
Albert W. Garofalo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain
Sven H. Schmidt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease
Vinicius M. Fava et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Coordinating a new approach to basic research into Parkinson's disease
Randy Schekman et al.
ELIFE (2019)
Peptides and peptidomimetics as inhibitors of protein-protein interactions involving β-sheet secondary structures
Jose Laxio Arenas et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2019)
Membrane association but not identity is required for LRRK2 activation and phosphorylation of Rab GTPases
Rachel C. Gomez et al.
JOURNAL OF CELL BIOLOGY (2019)
Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes
Emmanouela Leandrou et al.
BIOCHEMICAL JOURNAL (2019)
Roco Proteins: GTPases with a Baroque Structure and Mechanism
Lina Wauters et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Crystal structure of the WD40 domain dimer of LRRK2
Pengfei Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same
Daniel C. Berwick et al.
MOLECULAR NEURODEGENERATION (2019)
LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network
Zhiyong Liu et al.
HUMAN MOLECULAR GENETICS (2018)
Conformationally constrained peptides target the allosteric kinase dimer interface and inhibit EGFR activation
Melody D. Fulton et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages
Anetta Hartlova et al.
EMBO JOURNAL (2018)
Peptides as Potential Therapeutics for Alzheimer's Disease
Samo Ribaric
MOLECULES (2018)
14-3-3: A Case Study in PPI Modulation
Alice Ballone et al.
MOLECULES (2018)
LRRK2 kinase in Parkinson's disease
Dario R. Alessi et al.
SCIENCE (2018)
Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease
Ken Y. Hui et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
A motif within the armadillo repeat of Parkinson's-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway
Nasia Antoniou et al.
SCIENTIFIC REPORTS (2018)
The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties
Ryan D. Mills et al.
JOURNAL OF NEUROCHEMISTRY (2018)
LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis
Tomoya Eguchi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
LRRK2 activation in idiopathic Parkinson's disease
Roberto Di Maio et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity
Jillian H. Kluss et al.
NPJ PARKINSONS DISEASE (2018)
Rab29 activation of the Parkinson's disease-associated LRRK2 kinase
Elena Purlyte et al.
EMBO JOURNAL (2018)
Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
Andrew B. West
EXPERIMENTAL NEUROLOGY (2017)
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity
Jack D. Scott et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Structure-Based Design of Non-natural Macrocyclic Peptides That Inhibit Protein-Protein Interactions
Dennis M. Krueger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Rab32 connects ER stress to mitochondrial defects in multiple sclerosis
Yohannes Haile et al.
JOURNAL OF NEUROINFLAMMATION (2017)
A homologue of the Parkinson's disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover
Egon Deyaert et al.
NATURE COMMUNICATIONS (2017)
Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis
Martin Steger et al.
ELIFE (2017)
The LRR-Roc-COR module of the Chlorobium tepidum Roco protein: crystallization and X-ray crystallographic analysis
Egon Deyaert et al.
ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS (2017)
Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases
Aree Witoelar et al.
JAMA NEUROLOGY (2017)
Structural interface between LRRK2 and 14-3-3 protein
Loes M. Stevers et al.
BIOCHEMICAL JOURNAL (2017)
Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts
Giambattista Guaitoli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases
Martin Steger et al.
ELIFE (2016)
Revisiting the Roco G-protein cycle
Susanne Terheyden et al.
BIOCHEMICAL JOURNAL (2015)
Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration
Joao P. L. Daher et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
The ins and outs of selective kinase inhibitor development
Susanne Mueller et al.
NATURE CHEMICAL BIOLOGY (2015)
Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins
Sunny Rae Slone et al.
NEUROBIOLOGY OF DISEASE (2015)
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
Reina N. Fuji et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Higher Frequency of Certain Cancers in LRRK2 G2019S Mutation Carriers With Parkinson Disease A Pooled Analysis
Ilir Agalliu et al.
JAMA NEUROLOGY (2015)
The associations between Parkinson's disease and cancer: the plot thickens
Danielle D. Feng et al.
TRANSLATIONAL NEURODEGENERATION (2015)
Association of the LRRK2 genetic polymorphisms with leprosy in Han Chinese from Southwest China
D. Wang et al.
GENES AND IMMUNITY (2015)
Discovery and Preclinical Profiling of 3-[4-(Morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), A Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase Inhibitor
Jaclyn L. Henderson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibitions
Matthew J. Fell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Pharmacological Treatment of Parkinson Disease A Review
Barbara S. Connolly et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
The Parkinson Disease-linked LRRK2 Protein Mutation I2020T Stabilizes an Active State Conformation Leading to Increased Kinase Activity
Soumya Ray et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors
Anthony A. Estrada et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress
Loren D. Walensky et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1
Gregory C. Luerman et al.
JOURNAL OF NEUROCHEMISTRY (2014)
Prevalence of Cancer in Parkinson's Disease Related to R1441G and G2019S Mutations in LRRK2
Javier Ruiz-Martinez et al.
MOVEMENT DISORDERS (2014)
LRRK2-G2019S Mutation Is Not Associated With an Increased Cancer Risk: A Kin-Cohort Study
Roberta Allegra et al.
MOVEMENT DISORDERS (2014)
Stapled HIV-1 peptides recapitulate antigenic structures and engage broadly neutralizing antibodies
Gregory H. Bird et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3
Kathrin Muda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor
Bryan K. Chan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Characterization of TAE684 as a potent LRRK2 kinase inhibitor
Jinwei Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Leucine-rich repeat kinase 2 inhibitors: a patent review (2006-2011)
Xianming Deng et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
LRRK2 Parkinson disease mutations enhance its microtubule association
Lauren R. Kett et al.
HUMAN MOLECULAR GENETICS (2012)
Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors
Anthony A. Estrada et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Rational Design of Proteolytically Stable, Cell-Permeable Peptide-Based Selective Mcl-1 Inhibitors
Avinash Muppidi et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers
R. Inzelberg et al.
NEUROLOGY (2012)
Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations
Zejuan Sheng et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson's Disease-Related Toxicity in Human Neurons
Nigel Ramsden et al.
ACS CHEMICAL BIOLOGY (2011)
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2
Xianming Deng et al.
NATURE CHEMICAL BIOLOGY (2011)
Phosphorylation-Dependent 14-3-3 Binding to LRRK2 Is Impaired by Common Mutations of Familial Parkinson's Disease
Xianting Li et al.
PLOS ONE (2011)
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization
R. Jeremy Nichols et al.
BIOCHEMICAL JOURNAL (2010)
Phosphopeptide Analysis Reveals Two Discrete Clusters of Phosphorylation in the N-Terminus and the Roc Domain of the Parkinson-Disease Associated Protein Kinase LRRK2
Christian Johannes Gloeckner et al.
JOURNAL OF PROTEOME RESEARCH (2010)
LRRK2 G2019S Mutations are Associated with an Increased Cancer Risk in Parkinson Disease
Rachel Saunders-Pullman et al.
MOVEMENT DISORDERS (2010)
Kinase mutations in human disease: interpreting genotype-phenotype relationships
Piya Lahiry et al.
NATURE REVIEWS GENETICS (2010)
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
Mark R. Cookson
NATURE REVIEWS NEUROSCIENCE (2010)
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease
R. Jeremy Nichols et al.
BIOCHEMICAL JOURNAL (2009)
The Parkinson Disease Protein Leucine-Rich Repeat Kinase 2 Transduces Death Signals via Fas-Associated Protein with Death Domain and Caspase-8 in a Cellular Model of Neurodegeneration
Cherry Cheng-Ying Ho et al.
JOURNAL OF NEUROSCIENCE (2009)
Genomewide Association Study of Leprosy
Fu-Ren Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Structure of the Roc-COR domain tandem of C-tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase
Katja Gotthardt et al.
EMBO JOURNAL (2008)
The Roco protein family:: a functional perspective
Ignacio Marin et al.
FASEB JOURNAL (2008)
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
Jeffrey C. Barrett et al.
NATURE GENETICS (2008)
Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase
Junpeng Deng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity
Mahaboobi Jaleel et al.
BIOCHEMICAL JOURNAL (2007)
The Parkinson disease gene LRRK2:: Evolutionary and structural insights
Ignacio Marin
MOLECULAR BIOLOGY AND EVOLUTION (2006)
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity
CJ Gloeckner et al.
HUMAN MOLECULAR GENETICS (2006)
Using a β-hairpin to mimic an α-helix:: Cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction
R Fasan et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2004)
The PARK8 locus in autosomal dominant parkinsonism: Confirmation of linkage and further delineation of the disease-containing interval
A Zimprich et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
C Paisán-Ruíz et al.
NEURON (2004)
A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1
M Funayama et al.
ANNALS OF NEUROLOGY (2002)
Evolution of the 14-3-3 protein family: Does the large number of isoforms in multicellular organisms reflect functional specificity?
M Rosenquist et al.
JOURNAL OF MOLECULAR EVOLUTION (2000)
Share Paper
